George Eliades

Director at Oyster Point Pharma

George Eliades, Ph.D., is currently the Senior Vice President, Corporate Development and Chief Transformation Officer at Jazz Pharmaceuticals. From November 2007 to December 2020, Dr. Eliades was a partner at Bain & Company, where he focused primarily on advising biopharmaceutical clients at the company’s San Francisco and Zurich offices. Dr. Eliades has extensive experience supporting companies in oncology, neurology, endocrinology, ophthalmology and other specialty products. He brings deep experience in product launch and growth strategy. Dr. Eliades has advised multiple clients on their transformation agendas, including strategy, cost, M&A and digital driven transformation. Before joining Bain, Dr. Eliades was a consultant at Monitor Group serving global biopharmaceutical clients. Dr. Eliades serves as the Chairman of the Board of Directors for the Pulmonary Fibrosis Foundation and has also advised nonprofits in the healthcare space, including the California Life Sciences Association and the American Society of Retina Specialists. Dr. Eliades received a B.A. from Harvard College, and an M.A. and a Ph.D. from Harvard University.

Links

Timeline

  • Director

    Current role